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Abstract
ω3‐polyunsaturated free fatty acids (ω3‐PUFAs), particularly docosahexaenoic (DHA)
and eicosapentaenoic acid (EPA), are thought to exert health promoting effects in
metabolic and in inflammatory diseases. The molecular mechanisms of these benefi-
cial effects are only partially understood. DHA and EPA activate Free Fatty Acid
receptor 4 (GPR120/FFA4). Recently, the first orally available, synthetic ligand of
FFA4, 3‐[2‐chloro‐5‐(trifluoromethoxy)phenyl]‐3‐azaspiro[5.5]undecane‐9‐acetic acid
(“compound A”; cpd A) has been developed. Cpd A exhibits distinctly higher
potency, efficiency, and selectivity at FFA4 than ω3‐PUFAs and ameliorates insulin
resistance and adipose tissue inflammation in the mouse. With GPR120/FFA4 acti-
vation believed to also attenuate tissue inflammation in autoimmune diseases, cpd A
may also have a beneficial effect in these diseases. We have therefore addressed
the therapeutic potential of cpd A in mouse models of three prototypical autoim-
mune diseases, specifically psoriasis, rheumatoid arthritis, and bullous pemphigoid.
The effect of cpd A on the course of Aldara™‐induced psoriasis‐like dermatitis, K/
BxN serum transfer arthritis, and antibody transfer pemphigoid disease‐like dermati-
tis was scrutinized. Cpd A did not alter the course of Aldara‐induced psoriasis‐like
dermatitis, K/BxN serum transfer arthritis, or antibody transfer pemphigoid disease‐
like dermatitis. Our results suggest that therapeutic regimens solely relying on FFA4
activation do not bear the potential to treat inflammatory diseases. With cpd A dis-
tinctly more potent in activating GPR120/FFA4 than ω3‐PUFAs, this also suggests
that GPR120/FFA4 activation by ω3‐PUFAs does not significantly contribute to the
health‐promoting effects of ω3‐PUFAs in autoimmune diseases.
K E YWORD S
autoimmune disease, compound A, GPR120/FFAR4, pemphigoid disease, psoriasis, rheumatoid
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Abbreviations: ω3-PUFAs, ω3-polyunsaturated free fatty acids; DHA, docosahexaenoic; EPA, eicosapentaenoic acid; FFA4, Free Fatty Acid receptor 4; GPCR, G protein-coupled receptor.
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1 | INTRODUCTION
ω3‐polyunsaturated free fatty acids (ω3‐PUFAs), particularly docosa-
hexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are abundant
in fish oil and considered to exert health promoting effects.1 Thus,
high intake of fish oil has been associated with protection from
metabolic diseases, such as cardiovascular diseases and type II dia-
betes, as well as from chronic inflammatory diseases, including psori-
asis and rheumatoid arthritis.1-4 In line with this, the increase in the
incidence of chronic inflammatory diseases in Western societies
coincided with a shift in ω3‐ and ω6‐PUFA intake from a ratio ω6‐ to
ω3‐PUFAs of 1:1 to approximately 15:1.1
These associations have prompted numerous clinical trials
investigating the therapeutic potential of fish oil or purified esters
of DHA and EPA in different medical conditions. Among chronic
inflammatory diseases, their effect has most frequently been stud-
ied in psoriasis and in rheumatoid arthritis. The setup of these tri-
als was quite heterogeneous in respect to the ω3‐PUFAs
preparations, doses, and routes of administration used as well as
in respect to the features of the patient cohorts and the clinical
parameters used to benchmark therapeutic effects. The results of
these trials have recently been exhaustively summarized and ana-
lyzed in two systematic reviews.4,5 Collectively, most trials investi-
gating the effect in rheumatoid arthritis demonstrated moderate,
beneficial effects.5 The results on the therapeutic effects of ω3‐
PUFAs on psoriasis have been more contradictory with some trials
reporting beneficial effects, others finding no effect.4 The poten-
tial reasons for these conflicting results are manifold. An obvious
explanation is that the therapeutic potential of ω3‐PUFAs is too
moderate, thus, eliciting either no or only little suppression of dis-
ease activity in clinical trials including only small numbers of
patients. Further, ω3‐PUFAs may be only effective in certain
patient subgroups of the respective diseases. This situation precip-
itates the idea that compounds metabolically more stable than ω3‐
PUFAs and pharmacologically engaging the pathways downstream
of ω3‐PUFAs more potently than ω3‐PUFAs themselves may be
therapeutically more effective.
Mechanistically, the health‐promoting effects of ω3‐PUFAs are
thought to be implemented by multiple and diverse modes of action,
including the conversion of ω3‐PUFAs to proresolving lipid mediators
and PPARγ agonists, substrate competition with arachidonic acid,
thus, inhibiting the biosynthesis of proinflammatory eicosanoids,
including that of leukotriene B4 (LTB4), as well as changes in the bio-
physical properties of cell membranes.2,6
This concept of the molecular mode of action of ω3‐PUFAs
has been extended by another putatively most important mecha-
nism since DHA and EPA were identified as cognate ligands of
the G protein‐coupled receptor (GPCR) 120. GPR120 was deorph-
anized in 2005 to bind the ω3‐PUFAs docosahexaenoic acid
(DHA), and eicosapentaenoic acid (EPA), and α‐linolenic acid as
well as palmitoleic, myristic, and linoleic acid as agonistic, cognate
ligands.7,8 It was subsequently renamed Free Fatty Acid receptor 4
(FFA4) by the International Union of Basic and Clinical
Pharmacology.9 Recently, the group of natural GPR120/FFA4 ago-
nists has been extended by a class of newly discovered lipid medi-
ators: the branched fatty acid esters of hydroxy fatty acids
(FAHFAs) with the FAHFAs palmitic‐acid‐9‐hydroxy‐stearic‐acid (9‐
PAHSA) and palmitic‐acid‐5‐hydroxy‐stearic‐acid (5‐PAHSA) acti-
vate FFA4.10 In contrast to ω3‐PUFAs, mammals biosynthesize
PAHSAs. Thus, their identification as GPR120/FFA4 ligands marks
the discovery of endogenous ligands of FFA4, whose abundance is
independent of nutritional intake.
GPR120/FFA4 is widely expressed and is present on parenchy-
mal and epithelial cells of the gut, liver, adipose tissue, pancreas, and
taste buds. To date, most extensively investigated physiological role
of GPR120/FFA4 is its positive effect on insulin sensitivity, which
has sparked broad interest into the development of GPR120/FFA4
agonists as novel antidiabetics.11 In recent years, it has been shown
that FFA4 is also expressed on immune cells, including monocytes/
macrophages, dendritic cells, and eosinophils,8,10,12 suggesting that
GPR120/FFA4 may mediate immunomodulatory actions of ω3‐
PUFAs. In line with this notion, in vitro activation of GPR120/FFA4
in macrophages curbs their immune response to NLPR3 inflamma-
some, TLR4, or TNF‐α activation,13-15 and in vivo GPR120 is
required for ω3‐PUFAs to counteract adipose tissue inflammation
induced by high‐fat diet in mice by limiting the recruitment of mono-
cyte/macrophages into adipose and reducing the release of proin-
flammatory M1 macrophage‐derived immunomediators, such as IL‐
1β, TNF‐α, MCP‐1, and IL‐6, while in parallel promoting the expres-
sion of antiinflammatory M2 macrophages, such as IL‐10, arginase 1,
Ym‐1, and Clec7a.14 Notably, these same effects are replicated upon
activation of GPR120/FFA4 by the synthetic compound 3‐[2‐chloro‐
5‐(trifluoromethoxy)phenyl]‐3‐azaspiro[5.5]undecane‐9‐acetic acid,
also designated as compound A (cpd A).16 Cpd A is the first fully
selective, high‐affinity, and orally available GPR120/FFA4 agonist
and vastly surpasses the pharmacological potency of DHA in
GPR120/FFA4 activation in both man and mice,16 thus constituting
the first research tool allowing to delineate GPR120/FFA4 ‐mediated
actions in a highly specific manner. In mice, cpd A (30 mg/kg body
weight/day) improved glucose and insulin tolerance and inhibited
monocyte/macrophage migration toward adipose tissue‐derived
chemoattractants. Like ω3‐PUFAs, it promoted the establishment of
a M2 macrophage microenvironment in adipose tissue. Here, it also
enhanced the numbers of antiinflammatory Treg and Breg cells and
decreased the levels of LTB4.
16
These findings have not only highlighted GPR120/FFA4 agonists
as potential, novel class of antidiabetics, but also as possible new
therapeutic concept for the treatment of classical inflammatory dis-
eases.8 Studies on the effect of specific GPR120/FFA4 agonists on
the course of classical inflammatory diseases are currently, however,
not available yet. If effective, such a therapeutic strategy would be a
particularly attractive therapeutic strategy in chronic inflammatory
diseases often concurrent with type II diabetes, such as rheumatoid
arthritis, psoriasis, and bullous pemphigoid.17-19
In this study, we have addressed the therapeutic potential of cpd
A in mouse models of these three common, prototypical,
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autoimmune diseases using the Aldar™‐induced psoriasis‐like der-
matitis model, the K/BxN serum transfer model, and the antibody
transfer bullous pemphigoid‐like epidermolysis bullosa acquisita
mouse model, respectively.20-22 In all three models, cpd A did not
exhibit therapeutic efficiency, indicating that the antiinflammatory
effects, induced by GPR120/FFA4 activation, do not reach the level
to ameliorate clinically symptomatic tissue inflammation. Our results
therefore discourage the use of GPR120/FFA4 agonists in monother-
apeutic regimens in the treatment of inflammatory diseases.
2 | MATERIALS AND METHODS
2.1 | Mice
C57BL/6J wild‐type were purchased from JANVIER LABS (Saint‐
Berthevin Cedex, France). They were housed in a 12‐hour light‐dark
cycle in the animal facility of the University of Lübeck (Lübeck, Ger-
many) and fed with standard chow diet. All experiments were per-
formed in 8‐ to 12‐week‐old age‐ and sex‐matched mice by certified
personnel. All experiments had been permitted by the state govern-
ment of Schleswig‐Holstein.
2.2 | Preparation and administration of the FF4/
GPR120 agonist compound A
The FFA4/GPR120 agonist 3‐[2‐chloro‐5‐(trifluoromethoxy)phenyl]‐3‐
azaspiro[5.5]undecane‐9‐acetic acid (compound A; cpd A), previously
described,16 was purchased from Biomol GmbH (Hamburg, Ger-
many). Cpd A was solved in 10% DMSO in PBS. In all experiments,
50 mg/kg body weight cpd A was administered by oral gavage daily.
In the control group, the mice instead received only the vehicle, 10%
DMSO in PBS. Both, cpd A and its vehicle control were well toler-
ated throughout the experiments. In all three mouse models used in
this study, cpd A treatment was started 2 days before the first
induction of disease (day −2). This pretreatment regimen was chosen
to facilitate detecting possible beneficial effects of cpd A with
administration regimens aiming at suppressing emerging tissue
inflammation often exhibiting more pronounced effects than thera-
peutic regimens aiming at reversing established tissue inflammation.
2.3 | Induction and clinical evaluation of psoriasis‐
like dermatitis
To induce psoriasis‐like dermatitis, the Aldara™‐induced psoriasis‐like
dermatitis (AIPD) mouse model, in literature often also referred to as
“imiquimod‐induced psoriasis‐like dermatitis mouse model” was con-
ducted, as previously described.23,24 Briefly, a 2 × 3 cm large area
was depilated on the back 2 days before the first application of
Aldara™ cream (Meda, Solnau, Sweden). Starting from day 0, 50 mg
Aldara™ cream was daily applied on the back, and 5 mg on the dor-
sal surface of the ears for five consecutive days. On the back, the
severity of psoriasis‐like dermatitis was determined using the Psoria-
sis Activity and Severity Index (PASI). Thus, erythema, infiltration, and
desquamation were individually scored on a scale from 0 to 4 with
0, none; 1, mild; 2, moderate; 3, marked; 4; severe. Finally, the
scores of these individual aspects of dermatitis were summed up to
calculate the cumulative disease score. At the ear, the severity of
psoriasis‐like dermatitis was assessed by measuring the dorsal‐ventral
distance of the ear daily before the application of Aldara™cream
using a micrometer (Mitutoyo Europe, Neuss, Germany) and subse-
quently calculating ear swelling, i.e., the change of the dorsal‐ventral
distance compared to day 0.
2.4 | Induction and evaluation of arthritis
To induce arthritis, the K/BxN serum transfer model of rheumatoid
arthritis was used, as previously described.25,26 Thus, K/BxN serum
was harvested from 8‐week‐old arthritic K/BxN mice at the Semmel-
weis University (Budapest, Hungary) and stored at −80°C. For induc-
tion of arthritis, 150 μL of serum was injected i.p. into recipient mice
on days 0 and 2 of the experiment. Disease severity was assessed
using the following clinical score for each paw: 0, no signs of arthri-
tis; 1, localized edema/erythema on one surface of the paw; 2,
edema/erythema on the entirety of one surface of the paw; 3,
edema/erythema on both surfaces of the paw. Scores were summed
up for all four paws to obtain the composite score. Ankle thickness
was determined by micrometer (Mitutoyo Europe, Neuss, Germany).
Ankle thickening (ankle thickness compared to baseline on day 0)
was calculated as the mean difference between the current ankle
thickness and the ankle thickness on day 0. For histopathology,
ankles were dissected and fixed in 4% neutral buffered
paraformaldehyde, demineralized in modified Kristensen's solution,
and H&E stained. Stainings were visualized and photographed using
the BZ‐9000E series Keyence microscope (Keyence GmbH, Neu‐
Isenburg, Germany).
2.5 | Induction and clinical scoring of pemphigoid
disease‐like dermatitis
To generate pemphigoid disease‐like dermatitis in mice, the anti-
body transfer bullous pemphigoid‐like epidermolysis bullosa acqui-
sita (BP‐like EBA) mouse model was performed, as previously
described.27 Thus, in a first step, to generate IgG antibodies direc-
ted to type VII collagen (anti‐Col7 IgG), rabbits were immunized
against three epitopes of type VII collagen, and IgG directed to
the epitope C (anti‐Col7c IgG) was subsequently isolated from rab-
bit serum, as previously described.21 Purified anti‐Col7c IgG was
filter‐sterilized (pore size: 0.2 μm), and its concentration was
assessed by NanoDrop™ (ThermoFisher Scientific, Waltham, MA,
USA). The reactivity of each batch of anti‐Col7c IgG was checked
on murine tail skin sections by indirect immunofluorescence analy-
sis. To induce pemphigoid disease‐like dermatitis, mice were
injected s.c. with 50 μg of the affinity‐purified anti‐Col7c IgG on
days 0, 2, and 4 of the experiment. To score the severity of pem-
phigoid disease‐like dermatitis, skin areas exhibiting erythema, blis-
ters, erosions, crusts, or alopecia were categorized as “affected”,
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and, subsequently, the percentage of the total body surface
affected by skin lesions (ABSA) was calculated.
2.6 | Histopathology of the skin
For histopathology, biopsies of the skin were fixed in 4% Histofix® solu-
tion (Carl Roth, Karlsruhe, Germany), embedded in paraffin, cut into
6 μm sections, and subsequently H&E stained. Stainings were visualized
and photographed using the BZ‐9000E series Keyence microscope
(Keyence GmbH, Neu‐Isenburg, Germany). BZ‐II Analyzer software
(Keyence, Neu‐Isenburg, Germany) was used to measure epidermal
thickness, i.e., the distance between the dermal‐epidermal junction and
the epidermal in psoriasis‐like dermatitis, as previously described.23
2.7 | Immunofluorescence stainings
For IF stainings, skin biopsies were embedded in Tissue‐Tek® Cryomold®
(VWR, Darmstadt, Germany) before 6 μm sections were cut and stored
at −20°C until usage. To quantify epidermal cell proliferation in psoriasis‐
like skin lesions, sections were stained for Ki‐67 using rat antimurine Ki‐
67, biotinylated goat anti‐rat IgG (Biolegend, San Diego, CA, USA), and
DyLight 488‐streptavidin (Thermoscientific). The number of Ki‐67+ ker-
atinocytes per μm2 in the epidermis was quantified by BZ‐II Analyzer
software, as previously described.28 Alexa Fluor® 594 AffiniPure donkey
anti‐rabbit IgG (Jackson Immunoresearch, Suffolk, UK) and FITC‐conju-
gated goat anti‐mouse complement C3 IgG (MP Biomedicals, Illkirch,
France) were used to detect IgG and C3 depositions, respectively, in per-
ilesional skin of pemphigoid disease‐like dermatitis. Biotinylated rat anti‐
mouse Ly6G Ab (Biolegend, San Diego, CA, USA) was used in combina-
tion with DyLight 488‐conjugated streptavidin (ThermoFisher Scientific,
Waltham, MA, USA) to detect Ly6G+ cells. The BZ‐9000E series Keyence
microscope and BZ‐II Analyzer software (Keyence GmbH, Neu‐Isenburg,
Germany) were used to evaluate IF stainings throughout the study.
2.8 | Statistical analysis
All data are presented as mean ± SEM. Results were tested for sta-
tistical differences using GraphPad Prism 7.0 (GraphPad, San Diego,
CA, USA). P < 0.05 was considered statistically significant. Clinical
scores were compared by two‐way ANOVA with Sidak's multiple
F IGURE 1 Cpd A in psoriasis‐like
dermatitis. Psoriasis‐like dermatitis was
induced by daily application of Aldara™ on
the shaved back skin and the dorsal ears.
50 mg/kg body weight cpd A or vehicle
control was daily administered p.o. by
gavage starting 2 days prior to the first
application of Aldara™ (day −2). The
course of disease severity is shown with
the scores for (A) erythema, (B) infiltration,
and (C) desquamation, followed by (D) the
resulting cumulative score of (A)‐(C). (E)
Representative pictures of the clinical
presentation of psoriasis‐like dermatitis on
back skin on days 0 and 6. (F) Time course
of ear swelling in response to local
Aldara™ treatment. (G) H&E stainings of
back skin harvested day 6. (H) Epidermal
thickness of back skin on day 6. (I) Ki‐67
staining in back skin on day 6, and (J)
expression level of Ki‐67 in the skin
expressed as Ki‐67+ area HPF. One
representative of two independent
experiments is shown (n = 5 mice/group).
All results are presented as mean ± SEM.
Results in (A)‐(E) were tested for statistical
significance by two‐way ANOVA. Results
in (G) and (I) were analyzed by two‐sided,
unpaired Student's t test. Scale bars
represent 100 μm
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comparisons test. All data presented are representatives of at least
two independent experiments.
3 | RESULTS
3.1 | CpdA does not modulate the course of
psoriasis‐like dermatitis
To evaluate the potential of cpd A as therapeutic in psoriasis, we
induced psoriasis‐like skin inflammation in C57Bl/6 wild‐type mice, as
described in Methods, and treated one group of mice daily with cpd A
by gavage starting 2 days before the first application of Aldara™cream.
In parallel, the control group received only the vehicle (10% DMSO in
PBS). As expected, application of Aldara™induced skin inflammation
clinically and histopathologically resembling in major aspects human
plaque psoriasis. Thus, in both groups back skin exhibited signs of skin
inflammation, including erythema, infiltration, and desquamation, start-
ing on day 2 of the experiment and continuously rising until the end of
the experiment on day 6 (Figure 1A‐D). The severity of these signs of
inflammation was scored according to the Psoriasis Activity and Severity
Index (PASI), as described in Methods. Vehicle‐ and cpd A‐treated mice
did not differ in any of these individual aspects of psoriasis‐like skin
inflammation (Figure 1A‐E). We also measured ear swelling after appli-
cation of Aldara™to the ear in both groups, as an additional parameter
for the severity of skin inflammation (Figure 1F). Vehicle‐ and cpd A‐
treated mice did not differ in it either. Histopathological analysis con-
firmed that in both groups psoriasis‐like histopathological alterations
had occurred, including infiltration of the dermis with leukocytes and
lymphocytes, epidermal hyperproliferation as well as dermal neoangio-
genesis (Figure 1G). Staining for Ki‐67 and measuring of the epidermal
thickness revealed pronounced keratinocyte proliferation in both
groups (Figure 1H/I). Vehicle‐ and cpd A‐treated mice did not differ in
any of the listed hallmarks of psoriasis‐like skin inflammation, demon-
strating that cpd A treatment is not effective in ameliorating AIPD.
3.2 | Cpd A does not ameliorate antibody‐induced
arthritis
We next tested the effect of cpdA on antibody‐induced arthritis in
the K/BxN serum transfer model of rheumatoid arthritis. For this pur-
pose, cpd A or vehicle control was administered to C57BL/6 wild‐type
mice by gavage daily starting 2 days prior to the first application of K/
BxN serum. In both groups, K/BxN serum precipitated signs of arthri-
tis in fore‐ and hindpaws starting already 2 days after the first injec-
tion of K/BxN serum (Figure 2A‐C). Clinical severity of arthritis
steadily increased in both groups until the end of the experiment on
day 10 (Figure 2A). Likewise, arthritis differed between vehicle‐ and
cpdA‐treated mice when severity was assessed by ankle thickening
(Figure 2B). For both parameters, the clinical score and ankle thicken-
ing, the apparent difference between the two groups, however, did
not reach statistical significance probably primarily due to the low
magnitude of the therapeutic effect. We also compared the signs of
arthritis in the two groups on the histopathological level. Both groups
exhibited clear signs of arthritis, including leukocyte infiltration of
synovial tissues and into the synovial fluid, synovial fibroblast hyper-
proliferation, as well cartilage and bone erosion (Figure 2D). There
were no detectable differences between the two groups.
3.3 | Cpd A does not alter the course of
pemphigoid disease‐like dermatitis
We applied the antibody transfer BP‐like EBA mouse model as a
third prototypical example for a chronic inflammatory disease to
F IGURE 2 Cpd A in K/BxN serum transfer arthritis. Arthritis was
induced by i.p. injection of 150 μL K/BxN serum on days 0 and 2 of
the experiment. 50 mg/kg body weight cpd A or vehicle control was
daily administered p.o. by gavage starting 2 days prior to the first
application of K/BxN serum (day −2). The course of arthritis was
evaluated by determining (A) the clinical arthritis score and (B) ankle
thickening at the hindpaws. (C) Typical clinical presentation at the
hindpaws on day 10 of the experiment. (D) Representative
histopathologies of the hindpaws on day 10 presenting with
leukocyte infiltrates, synovial fibroblast hyperplasia, and bone and
cartilage erosions. The presented are merged from two independent
experiments with 10 mice per group in total. All results are
presented as mean ± SEM. Results in (A) and (B) were tested for
statistical significance by two‐way
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further explore the therapeutic potential of cpd A. We started the
administration of cpd A 2 days prior to the first application of anti‐
Col7 IgG. In both vehicle‐ and cpd A‐treated mice, pemphigoid dis-
ease‐like dermatitis became apparent by day 4 of the experiment
and plateaued on day 8 without a significant difference between the
two groups (Figure 3A/B). Likewise, on the histopathological level,
both groups showed typical pemphigoid disease‐like alterations with
a pronounced infiltration of the dermis with granulocytes and
subepidermal clefting with no difference between the two groups
(Figure 3C).
As in all our disease models cpd A did not exhibit any effect on
the course of disease, we scrutinized the general pharmacological
activity of the cpd A distributed from our manufacturer by examining
the effect of this cpd A on ROS release from Raw 264.7 macro-
phages. Similar to what had previously been described for other
GPR120/FFA4 agonists,29 Cpd A dose‐dependently inhibited PMA‐
induced ROS release from Raw 264.7 macrophages (Figure S1).
4 | DISCUSSION
High intake of ω3‐PUFAs is associated with protection from a wide
spectrum of inflammatory diseases, including rheumatoid arthritis
and psoriasis. Accordingly, the therapeutic potential of ω3‐PUFAs
has been evaluated in several clinical studies, which, in sum, suggest
that the therapeutic administration of ω3‐PUFAs, if at all, only exerts
moderate therapeutic effects.4,30 Thus, to exploit the molecular
mechanisms, applied by ω3‐PUFAs, small molecules, which more
potently activate these mechanisms and are pharmacologically better
controllable and predictable in their effects than ω3‐PUFAs, are
required. In pursuit of this goal, we have scrutinized here the thera-
peutic potential of the first orally available GPR120/FFA4 agonist,
cpd A, in three mouse models of prototypic inflammatory diseases.
Although cpd A is in its agonistic, pharmacological properties
toward GPR120/FFA4 far superior to ω3‐PUFAs,16 it did not modu-
late the severity of disease in any of the three mouse models,
F IGURE 3 Cpd A in pemphigoid disease‐like dermatitis. Pemphigoid‐like dermatitis was induced by s.c. injection of 50 μg anti‐Col7c IgG on
days 0, 2, and 4 of the experiment. 50 mg/kg body weight cpd A or vehicle control was daily administered p.o. by gavage starting 2 days prior
to the first application of anti‐Col7c IgG (Day −2). (A) Clinical severity of dermatitis evaluated by the percentage of the total body surface
affected by pemphigoid disease‐like skin lesions. (B) Typical clinical presentation of pemphigoid disease‐like dermatitis with erythema, erosions,
crusts, and alopecia on day 12. (C) H&E stainings of lesional skin on day 12. Arrows indicate subepidermal clefts, the signature lesion of
pemphigoid diseases (1st panel). IgG and C3 deposition at the dermal‐epidermal junction, indicated by white arrows, in perilesional skin on day
12 (second and third panel, respectively). One representative of three independent experiments is shown (n = 10 mice/group). All results are
presented as mean ± SEM and were analyzed for statistical significance by two‐way ANOVA. Scale bars represent 100 μm
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indicating that activation of GPR120/FFA4 alone is not sufficient to
attenuate tissue inflammation, but may require the multimodal phar-
macodynamic actions of ω3‐PUFAs. This notion is supported by the
attenuation of tissue inflammation in the AIPD and the K/BxN serum
transfer model in fat-1 mice.31,32 fat-1 mice transgenically express
the enzyme n‐3 desaturase, derived from the roundworm Caenorhab-
ditis elegans, and, consequently, continuously biosynthesize large
quantities of ω3‐PUFAs from ω6‐PUFAs in all their tissues.33 One
contributory, molecular mechanism may be the biosynthesis of
proresolving lipid mediators. Accordingly, deficiency in 12/15‐lipoxy-
genase, a key enzyme in the biosynthesis of ω3‐PUFA‐derived prore-
solving lipid mediators, aggravates K/BxN serum transfer arthritis,34
thus hinting at the in vivo relevance of counterregulatory effects of
proresolving lipid mediators to contain tissue inflammation in vivo.
In our experiments, we started the administration of cpd A
2 days before the induction of disease. Oh et al, in contrast, treated
with cpd A for 5 weeks before detecting a statistically significant
improvement in insulin resistance. Such a long‐term administration
of GPR120/FFA4 agonists may be required to gradually induce
changes in the tissue, implementing an antiinflammatory tissue
microenvironment preserving tissue homeostasis and counteracting
emerging inflammation. Hence, it is conceivable that continuous
long‐term administration of cpd A well in advance to the induction
of tissue inflammation does exert more effects than acute applica-
tion of cpd A. Higher efficiency of cpd A under long‐term application
may render cpd A effective preventive drug in these diseases, which
would be of interest because all three prototypical diseases included
in this study typically proceed in cycles of acute flares and partial
remissions. Similarly, although we already applied a higher dose of
cpd A than Oh et al, it still cannot be excluded that an even higher
dose might have been more effective attenuating disease in one or
the other of the three mouse models applied here. A caveat of stud-
ies is that cpd A plasma levels were not assessed, thus, complicating
the comparison of the results of the two studies with each other
and with possible future studies.
Notably, the in vivo significance of GPR120/FFA4 to suppress
chronic low‐grade inflammation also has lately been contended. While
GPR120/FFA4 activation by ω3‐PUFAs was initially reported to be
critical to reduce high‐fat diet‐induced adipose tissue inflammation,14
more recent studies found GPR120/FFA4 to be dispensable for the
therapeutic effects of ω3‐PUFAs in mouse models of both high‐fat
diet‐induced adipose tissue inflammation, and of atherosclerosis.35,36
The reason for these discrepant findings is unknown and numerous
explanations are conceivable. Inflammation is a most complex process
and ω3‐PUFAs can exert diverse pharmacological actions independent
of GPR120/FFA4. It would not be surprising if the relative contribu-
tion of GPR120 to regulate tissue inflammation varies depending on
the detailed conditions of the organism. The conditions under which
GPR120/FFA4 activation elicits antiinflammatory effects in vivo there-
fore must be exactly defined.
In conclusion, our results suggest that targeting GPR120/FFA4
alone is not a promising concept for the development of new treat-
ments for diseases featuring acute tissue inflammation. Future
studies should, therefore rather, address whether small molecules
individually engaging other molecular mechanisms contributing to
the putative beneficial effects of ω3‐PUFAs, such as the receptors
for proresolving lipid mediators, are more effective than GPR120/
FFA4 engagement in ameliorating tissue inflammation. Alternatively,
multipronged therapeutic strategies, in parallel engaging several of
these molecular mechanisms to elicit relevant therapeutic effects,
may be examined.
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